Press Room
Recent Press Releases
-
March 07, 2019
Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies -
March 06, 2019
Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance -
March 06, 2019
Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women -
March 06, 2019
Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection -
March 05, 2019
Gilead Announces Senior Management Change
Media Inquiries
For additional information about our work, please contact the Gilead public affairs team by calling 1-800-GILEAD-5
Company Statements
Find important Gilead announcements, leadership perspectives, and other corporate communications.